Table 2.

Primary and secondary study outcomes

	Overall population					Matched population
	Use n = 10 419 events/1000 pt-yr (95% CI)	Non-use n = 2002events/1000 pt-yr (95% CI)	IRR (95% CI)	HR (95% CI)	PS adjusted HR (95% CI)	Use n = 10 419 events/1000 pt-yr (95% CI)	Non-use n = 2002	IRR (95% CI)events/1000 pts-yr (95% CI)	HR (95% CI)
	RASI/ARNI
CV mortality/HFH	160 (156–164)	364 (345–385)	0.44^ (0.41–0.47)	0.50^ (0.47–0.53)	0.91^ (0.85–0.97)	314 (297–332)	350 (331–370)	0.89^ (0.83–0.97)	0.90* (0.83–0.98)
All-cause mortality	123 (120–127)	316 (300–331)	0.39^ (0.37–0.41)	0.40^ (0.38–0.42)	0.78^ (0.73–0.83)	241 (228–254)	305 (290–321)	0.79^ (0.73–0.85)	0.75^ (0.69–0.81)
CV mortality	74 (71–76)	192 (180–204)	0.38^ (0.36–0.41)	0.40^ (0.37–0.43)	0.81^ (0.75–0.88)	157 (147–167)	185 (173–197)	0.85^ (0.77–0.93)	0.84^ (0.76–0.92)
HFH	123 (119–127)	245 (229–262)	0.50^ (0.47–0.54)	0.59^ (0.54–0.63)	0.98 (0.91–1.07)	231 (216–246)	238 (222–254)	0.97 (0.88–1.07)	0.99 (0.90–1.09)
	Beta-blockers
CV mortality/HFH	173 (169–178)	247 (231–264)	0.70^ (0.65–0.75	0.74^ (0.69–0.80)	0.89^ (0.82–0.96)	194 (181–208)	246 (230–263)	0.79^ (0.72–0.87)	0.82^ (0.74–0.90)
All-cause mortality	136 (132–139)	214 (201–228)	0.63^ (0.59–0.68)	0.64^ (0.60–0.69)	0.85^ (0.79–0.91)	169 (158–180)	212 (199–226)	0.80^ (0.73–0.87)	0.79^ (0.72–0.87)
CV mortality	81 (78–84)	130 (120–140)	0.62^ (0.57–0.68)	0.64^ (0.58–0.70)	0.86^ (0.78–0.94)	104 (96–113)	129 (119–140)	0.81^ (0.72–0.91)	0.80^ (0.71–0.90)
HFH	131 (127–135)	175 (162–189)	0.75^ (0.69–0.81)	0.80^ (0.74–0.87)	0.90* (0.82–0.98)	138 (127–150)	161 (174–188)	0.79^ (0.71–0.89)	0.86^ (0.76–0.96)

CI, confidence interval; CV, cardiovascular; HFH, heart failure hospitalization; HR, hazard ratio; IRR, incidence rate ratio; PS, propensity score; RASI/ARNI, renin–angiotensin system inhibitors/angiotensin receptor neprilysin inhibitor.

* P-value < 0.05.

^P-value < 0.01.